Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | MI-503 |
Trade Name | |
Synonyms | MI 503|MI503 |
Drug Descriptions |
MI-503 inhibits the interaction between Menin and MLL (KMT2A), potentially decreasing growth and migration of tumor cells (PMID: 25817203, PMID: 29142068). |
DrugClasses | MEN1-KMT2A Inhibitor 8 |
CAS Registry Number | 1857417-13-0 |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Enzalutamide + MI-503 | Enzalutamide MI-503 | 0 | 0 |
Gilteritinib + MI-503 | Gilteritinib MI-503 | 0 | 0 |
MI-503 | MI-503 | 1 | 0 |
MI-503 + Ponatinib | MI-503 Ponatinib | 0 | 0 |
MI-503 + Quizartinib | MI-503 Quizartinib | 0 | 0 |
MI-503 + Sorafenib | MI-503 Sorafenib | 0 | 0 |